Literature DB >> 22643569

Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.

Seza A Gulec1, Kenneth Pennington, James Wheeler, Tushar C Barot, Rekha R Suthar, Michael Hall, Douglas Schwartzentruber.   

Abstract

OBJECTIVES: Selective internal radiation therapy (SIRT) with yttrium-90 (Y) microspheres has emerged as an effective liver-directed therapy with a favorable therapeutic ratio for treatment of colorectal cancer liver metastases. The aim of this study was to investigate the objective responses obtained by Y microsphere treatment when combined with contemporary chemotherapy in the front-line (first or second line) setting in patients with CRCLM.
METHODS: This study used an in vivo comparison between the right and left liver lobes; systemic chemotherapy was supplied to both liver lobes by virtue of systemic administration, whereas SIRT was administered selectively to the target liver lobe only. Response to treatment was evaluated by serial fludeoxyglucose positron emission tomography computed tomography performed at 4 weeks, 2 to 4 months, and 6 to 8 months. Standard uptake value, anatomic volume, functional tumor volume, and total lesion glycolysis (TLG) calculations were obtained at each time point.
RESULTS: A decrease in TLG on fludeoxyglucose positron emission tomography computed tomography imaging was seen in 19 of the 20 patients. The mean decrease in TLG values in the tumors receiving chemo-SIRT and chemo-only treatment were 86.26%±18.57% and 31.74%±80.99% (P<0.01), 93.13%±11.81% and 40.80%±73.32% (P=0.01), and 90.55%±19.75% and 54.91%±38.55% (P<0.01) at 4 weeks, 2 to 4 months, 6 to 8 months posttreatment, respectively. Functional and anatomic tumor volume changes were in concordance with the TLG changes.
CONCLUSIONS: The study demonstrated that, under near identical conditions in terms of patient and tumor characteristics, the chemo-SIRT combination produced superior objective responses compared with chemo-only treatment in a front-line treatment setting in patients with colorectal cancer liver metastases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22643569     DOI: 10.1097/COC.0b013e3182546c50

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  16 in total

Review 1.  Liver-directed treatments for metastatic colorectal cancer.

Authors:  Michael A Choti
Journal:  Curr Treat Options Oncol       Date:  2014-09

Review 2.  Colorectal hepatic metastasis: Evolving therapies.

Authors:  Francisco Igor B Macedo; Tafadzwa Makarawo
Journal:  World J Hepatol       Date:  2014-07-27

3.  ALPPS: Adverse Outcomes Demand Clear Justification in an Era of Improving Survival for Colorectal Liver Metastases.

Authors:  Sanjeev Rohatgi; Ewen M Harrison; James J Powell; Stephen J Wigmore
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

Review 4.  Intra-arterial therapies for metastatic colorectal cancer.

Authors:  David S Wang; John D Louie; Daniel Y Sze
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 5.  Trial Watch: Radioimmunotherapy for oncological indications.

Authors:  Norma Bloy; Jonathan Pol; Gwenola Manic; Ilio Vitale; Alexander Eggermont; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 6.  [Contralateral hepatic hypertrophy following unilateral yttrium-90 radioembolization : Implications for liver surgery].

Authors:  B Garlipp; M Seidensticker; D Jechorek; H Ptok; C J Bruns; J Ricke
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

7.  Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.

Authors:  Andrew S Kennedy; David S Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Samir Kanani; Charles W Nutting; Fred M Moeslein; Samuel G Putnam; Steven C Rose; Michael A Savin; Sabine Schirm; Navesh K Sharma; Eric A Wang
Journal:  J Gastrointest Oncol       Date:  2015-12

Review 8.  Yttrium-90 microspheres: a review of its emerging clinical indications.

Authors:  Natthida Khajornjiraphan; Nyein Aye Thu; Pierce Kah Hoe Chow
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

9.  Semi-Quantitative Analysis of Post-Transarterial Radioembolization (90)Y Microsphere Positron Emission Tomography Combined with Computed Tomography (PET/CT) Images in Advanced Liver Malignancy: Comparison With (99m)Tc Macroaggregated Albumin (MAA) Single Photon Emission Computed Tomography (SPECT).

Authors:  Seunghong Rhee; Sungeun Kim; Jaehyuk Cho; Jukyung Park; Jae Seon Eo; Soyeon Park; Eunsub Lee; Yun Hwan Kim; Jae-Gol Choe
Journal:  Nucl Med Mol Imaging       Date:  2015-09-14

10.  Locally targeted delivery of a micron-size radiation therapy source using temperature-sensitive hydrogel.

Authors:  Yusung Kim; Dong Rim Seol; Sucheta Mohapatra; John J Sunderland; Michael K Schultz; Frederick E Domann; Tae-Hong Lim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.